United States, May 26 -- The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis (scarring), liver cancer, liver failure, and even death. HDV infection only occurs in individuals who have hepatitis B virus (HBV) infection. Some risk factors for contracting HDV include unprotected sex, injecting drugs, and occupational exposure to blood. HBV vaccination protects against HBV and HDV as well.The efficacy of Hepcl...